Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Megan Wollerton Following a new round of testing, we have added a number of ...